The Pharma Data

APRIL 8, 2021

Roy Baynes, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories. Most cases of RCC are discovered incidentally during imaging tests for other abdominal diseases. Merck has the industry’s largest immuno-oncology clinical research program.

Therapies 52

Therapies Disease Research Laboratories Treatment 52

The Pharma Data

JULY 8, 2021

This approval is based on data from the second interim analysis of the Phase 2 KEYNOTE-629 trial, in which KEYTRUDA demonstrated an objective response rate (ORR) of 50% (95% CI, 36-64) (n=54), including a complete response rate of 17% and a partial response rate of 33% in the cohort of patients with locally advanced disease.

FDA Approval 52

FDA Approval FDA Treatment Therapies 52

The Pharma Data

JULY 6, 2021

Food and Drug Administration (FDA)-approved test, with disease progression on or after two or more prior lines of therapy including fluoropyrimidine- and platinum-containing chemotherapy and if appropriate, human epidermal growth factor receptor 2 (HER2)/neu-targeted therapy. 1)] as determined by a U.S. Head and Neck Squamous Cell Cancer.

FDA Approval 52

FDA Approval FDA Treatment Therapies 52

The Pharma Data

MARCH 16, 2021

inhibitor belzutifan (pronounced bell-ZOO-ti-fan), a novel investigational candidate in Merck’s oncology pipeline, for the potential treatment of patients with von Hippel-Lindau (VHL) disease-associated renal cell carcinoma (RCC), not requiring immediate surgery. in patients with VHL disease-associated RCC. In the U.S.

FDA 52

FDA Disease Trials Drugs 52

The Pharma Data

JUNE 25, 2021

First-Time Disease-Free Survival Data to be Presented During Plenary Session at the 2021 ASCO Annual Meeting. 41.5), KEYTRUDA demonstrated a statistically significant and clinically meaningful reduction in the risk of disease recurrence or death by 32% compared to placebo (HR=0.68 [95% CI, 0.53–0.87]; KENILWORTH, N.J.–(BUSINESS

Disease 52

Disease Therapies Treatment Medical Schools 52

The Pharma Data

AUGUST 10, 2021

The FDA’s acceptance of our application adds to our momentum of advancing new treatment options to address the most challenging cancers facing women,” said Dr. Scot Ebbinghaus, vice president, clinical research, Merck Research Laboratories. Merck has the industry’s largest immuno-oncology clinical research program.

FDA 52

FDA Therapies Treatment Clinical Research 52

The Pharma Data

MARCH 17, 2021

KEYTRUDA reduced the risk of disease progression or death by 35% (HR=0.65 [95% CI, 0.48-0.88]; We are driven to advance therapies to help improve outcomes for patients with blood cancers, including those with relapsed or refractory classical Hodgkin lymphoma, through our broad clinical program.”. months versus 8.3 months (95% CI, 10.9-19.4)

Therapies 52

Therapies Treatment Disease Trials 52

The Pharma Data

JUNE 29, 2021

0.86]; p<0.0001) and reduced the risk of disease progression or death by 35% (HR=0.65 [95% CI, 0.55-0.76]; 0.78]; p<0.0001) and reduced the risk of disease progression or death by 49% (HR=0.51 [95% CI, 0.41-0.65]; Patients could be treated with KEYTRUDA for up to 24 months in the absence of disease progression.

Therapies 52

Therapies Treatment Disease Clinical Research 52

The Pharma Data

JULY 15, 2021

0.82]; p=0.00031) versus the chemotherapy-placebo regimen – a statistically significant and clinically meaningful EFS result. EFS was defined as the time from randomization to the first occurrence of either disease progression that precluded definitive surgery, a local/distant recurrence, a second primary cancer, or death from any cause.

Therapies 52

Therapies Treatment Trials FDA 52

The Pharma Data

MARCH 23, 2021

0.86]; p<0.0001) and reduced the risk of disease progression or death by 35% (HR=0.65 [95% CI, 0.55-0.76]; We are committed to putting patients first and continuing our research to help advance new approaches to potentially extend the lives of people with cancer. Ninety-one percent had M1 disease, and 9% had M0 disease.

Treatment 52

Treatment FDA Approval FDA Therapies 52

The Pharma Data

JULY 22, 2021

Immunotherapy and Tyrosine Kinase Inhibitor Combination Approved for the Treatment of Patients With Advanced Endometrial Carcinoma That is Not Microsatellite Instability-High or Mismatch Repair Deficient, Who Have Disease Progression Following Prior Systemic Therapy in Any Setting and Are Not Candidates for Curative Surgery or Radiation.

Therapies 52

Therapies Treatment Disease Trials 52

The Pharma Data

SEPTEMBER 7, 2021

“In China, esophageal and gastroesophageal junction cancers are leading causes of death, and there have been few treatment advances for patients over the past several decades,” said Dr. Scot Ebbinghaus, vice president, clinical research, Merck Research Laboratories. The median OS was 12.4 months (95% CI, 10.5-14.0)

Treatment 52

Treatment Research Laboratories Packaging Laboratories 52

The Pharma Data

SEPTEMBER 1, 2021

Headquartered in Miami, Florida, Ridgeback Biotherapeutics LP is a biotechnology company focused on emerging infectious diseases. The team at Ridgeback is dedicated to working toward finding life-saving and life-changing solutions for patients and diseases that need champions. Data from the study is expected in the second half of 2021.

Laboratories 52

Laboratories Clinical Trials Virus Trials 52

Codon

JULY 21, 2024

Of course, AA and P-line rats are not the only research animals bred for the study of disease. The most famous of these is the Oncomouse , engineered in 1984 for the express purpose of developing tumors so that researchers could study cancer in living organisms, rather than in petri dishes. 1 Subscribe to Asimov Press.

Research 126

Research Engineering Disease Science 126

The Pharma Data

APRIL 4, 2023

Patients were treated until disease progression or unacceptable toxicity. Thirty-seven percent of patients had upper tract disease. Merck has the industry’s largest immuno-oncology clinical research program. A total of 121 patients received KEYTRUDA in combination with enfortumab vedotin. At baseline, 97.5%

Treatment 40

Treatment FDA Approval FDA Therapies 40

The Pharma Data

SEPTEMBER 28, 2021

10) and who haven’t received prior chemotherapy for metastatic disease. Triple-negative carcinoma grows and spreads faster than other sorts of carcinoma and consequently features a worse prognosis,” said Dr. Vicki Goodman, vice chairman , clinical research, Merck Research Laboratories. Source link: [link].

Research Laboratories 52

Research Laboratories Clinical Research Treatment Disease 52

The Pharma Data

NOVEMBER 22, 2020

Baynes, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories. Islatravir is a promising antiviral candidate with evidence from ongoing clinical trials to support its development as a once-monthly oral PrEP agent. Forward-Looking Statement of Merck & Co.,

Trials 52

Trials Clinical Trials International Production 52

Broad Institute

NOVEMBER 6, 2024

When we launched the SIC service, Chloé had just joined MGH and the Broad to start her independent research laboratory, and when our department heads heard about our shared interest, they connected us on a “scientific blind date.”

Research 131

Research Immune Response Hospitals Therapies 131